Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Jun 2017

Gangaraju Radhika, Kim Soo J, Dong Jing-Fei, Swierczek Sabina, Prchal Josef T

Abstract excerpt

Pegylated interferon alfa-2a (pegIFNa) is being increasingly used for treatment of myeloproliferative neoplasms; however, its side effects, including autoimmune complications, are not unusual. We report on a 47-year-old woman with polycythemia vera (PV) treated with pegIFNa and in complete hematologic remission who developed thrombotic thrombocytopenic purpura (TTP). To our knowledge, thrombotic microangiopathy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Cell Count
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Polyethylene Glycols

Share to Purpura, Thrombotic Thrombocytopenic

Share to Recombinant Proteins

Source

Identifiers

PMID: 28596255
DOI: 10.6004/jnccn.2017.0108

Genes

ADAMTS13

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.PMID 28596255Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia veraSemantic proximity Read ↗

Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

A Case of Coomb’s Negative Hemolysis Post-mRNA COVID-19 Vaccine in a Patient With Polycythemia VeraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.